Current Concepts of Coagulation and Fibrinolysis

Advances in Clinical Chemistry

Volumn 33, Issue C, 1998, Pages 133-168

  Narayanan, Sheshadri ^a   Hamasaki, Naotaka ^b  

^a METROPOLITAN HOSPITAL CENTER   (United States)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ANIMAL; BLOOD; BLOOD CLOTTING; BLOOD CLOTTING TEST; DRUG EFFECT; FIBRINOLYSIS; HEMOSTASIS; HUMAN; LEUKOCYTE; METABOLISM; METHODOLOGY; PHYSIOLOGY; REFERENCE VALUE; REVIEW; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOPHILIA;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; BLOOD PLATELETS; FIBRINOLYSIS; HEMOSTASIS; HUMANS; LEUKOCYTES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; REFERENCE VALUES; THROMBOPHILIA;

EID: 0032242749     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2423(08)60207-3     Document Type: Article

References (119)

1. Kroll M.H., Harris T.S., Moake J.L., Handin R.I., and Shafer A.I. Von Willebrand factor binding to platelet GP Ib initiates signals for platelet activation. J Clin Invest 88 (1991) 1568-1573
2. Tandon N.N., Kralisz U., and Jamieson G.A. Identification of glycoprotein IV (CD36) as a primary receptor for platelet collagen adhesion. J Biol Chem 264 (1989) 7576-7583
3. Asch A.S., Barnwell J., Silverstein R.L., and Nachman R.L. Isolation of the thromboplastin membrane receptor. J Clin Invest 79 (1987) 1054-1061
4. Hynes R.D. Integrins: A family of cell surface receptors. Cell 48 (1987) 549-554
5. Lefkovits J., Plow E.F., and Topol E. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 332 (1995) 1553-1559
6. Ginsberg M.H., Xiaoping D., O'Toole T.E., Loftus J.C., and Plow E.F. Platelet integrins. Thromb Haemost 70 (1993) 87-93
7. Berridge M.J. Inositol triphosphate and diacylglycerol: Two interacting second messengers. Annu Rev Biochem 56 (1987) 159-193
8. Narayanan S. Inhibition of platelet aggregation and release and fibrinolysis. Ann Clin Lab Sci 19 (1989) 260-265
9. Zwaal R.F.A., and Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89 (1997) 1121-1132
10. Kalafatis M., Swords N.A., Rand M.D., and Mann K.G. Membrane-dependent reactions in blood coagulation: Role of Vitamin K-dependent enzyme complexes. Biochim Biophys Acta 1227 (1994) 113-129
11. Nemerson Y. The tissue factor pathway of blood coagulation. Semin Hematol 29 (1992) 170-176
12. Philippou H., Adami A., Amersey R.A., Stubbs P.J., and Lane D.A. A novel specific immunoassay for plasma two-chain factor VIIa: Investigation of F VIIa levels in normal individuals and in patients with acute coronary syndromes. Blood 89 (1997) 767-775
13. Von dem Borne P.A.K., Meijers J.C.M., and Bouma B.N. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 86 (1995) 3035-3042
14. Asakai R., Chung D.W., Davie E.W., and Seligsohn U. Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med 325 (1991) 153-158
15. Stubbs M.T., and Bode W. A player of many parts: The spot light falls on thrombin's structure. Thromb Res 69 (1993) 1-58
16. Tulinsky A. Molecular interaction of thrombin. Semin Thromb Hemost 22 (1996) 117-124
17. McDonagh J., and Fukue H. Determinants of substrate specificity for factor XIII. Semin Thromb Hemost 22 (1996) 369-376
18. McGee M.P., and Li L.C. Functional difference between intrinsic and extrinsic coagulation pathways. Kinetics of factor X activation on human monocytes and alveolar macrophages. J Biol Chem 266 (1991) 8079-8085
19. Edwards R.L., and Rickles F.R. The role of leukocytes in the activation of blood coagulation. Semin Hematol 29 (1992) 202-212
20. Altieri D.A. Coagulation assembly on leukocytes in transmembrane signaling and cell adhesion. Blood 81 (1993) 569-579
21. Tracy P.B., Rorhbach M.S., and Mann K.G. Functional prothrombinase complex assembly on isolated monocytes and lymphocytes. J Biol Chem 258 (1983) 7264-7267
22. Nesheim M., Blackburn M.N., Lawler C.M., and Mann K.G. Dependence of antithrombin III and thrombin binding stoichiometrics and catalytic activity on the molecular weight of affinity purified heparin. J Biol Chem 261 (1986) 3214-3221
23. Rosenberg R.D., and Damus P.S. The purification and mechanism of action of human antithrombin-heparin co-factor. J Biol Chem 248 (1973) 6490-6505
24. Travis J., and Salvesen G.S. Human plasma proteinase inhibitors. Annu Rev Biochem 52 (1983) 655-709
25. Scott R.W., Eaton D.L., Duran N., and Baker J.B. Regulation of extracellular plasminogen activator by human fibroblasts. The role of protease nexin. J Biol Chem 258 (1983) 4397-4403
26. Van Nostrand W.E., Schmaier A.H., Farrow J.S., and Cunningham D.D. Protease nexin-II (amyloid β-protein precursor): A platelet α granule protein. Science 248 (1990) 745-748
27. Broze Jr. G.J. The role of tissue factor pathway inhibitor in a revised coagulation cascade. Semin Hematol 29 (1992) 159-169
28. Novotny W.F., Palmier M.O., Wun T.C., et al. Purification and properties of heparin releasable lipoprotein-associated inhibitor. Blood 78 (1991) 394-400
29. Novotny W.F., Girard T.J., Miletich J.P., and Broze G.J. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72 (1988) 2020-2025
30. Esmon C.T., Ding W., Yasuhiro K., et al. The protein C pathway: New insights. Thromb Haemost 78 (1997) 70-74
31. Nesheim M., Wang W., Bofta M., et al. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb Haemost 78 (1997) 386-391
32. Machovich R., and Owen W.G. An elastase-dependent pathway of plasminogen activation. Biochemistry 28 (1989) 4517-4522
33. Lucas M.A., Fretto L.S., and McKee P.A. The relationship of fibrinogen structure to plasminogen activation and plasmin activity during fibrinolysis. Ann N Y Acad Sci 408 (1983) 71-91
34. Holt J.C., Mahmoud M., and Gaffney P.J. The ability of fibrinogen fragments to support ADP-induced platelet aggregation. Thromb Res 16 (1979) 427-435
35. La Duca F.M. Stimulation of fibrinogen synthesis in cultured rat hepatocytes by fibrinogen degradation product fragment D. Proc Natl Acad Sci USA 86 (1989) 8788-8792
36. Bachman F., and Kruithof E.K.O. Tissue plasminogen activator chemical and physiological aspects. Semin Thromb Hemost 10 (1984) 6-17
37. Bell W.R. The fibrinolytic system in neoplasia. Semin Thromb Hemost 22 (1996) 459-478
38. Lijnen H.R., Zamarron C., and Blaber M. Activation of plasminogen by prourokinase. I. Mechanism. J Biol Chem 261 (1986) 1253-1258
39. Fazioli F., and Blasi F. Urokinase-type plasminogen activator and its receptor: New target for anti-metastatic therapy?. Trends Pharmacol Sci 15 (1994) 25-29
40. Schmaier A.H. Contact activation: A revision. Thromb Haemost 78 (1997) 101-107
41. Robbins K.C., Barlow G.H., Nguyen G., and Samama M.M. Comparison of plasminogen activators. Semin Thromb Hemostas 13 (1987) 131-138
42. Sprengers E.D., and Kluft C. Plasminogen activator inhibitors. Blood 69 (1987) 381-387
43. Levin E.G., and Santell L. Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. J Cell Biol 105 (1987) 2543-2549
44. Heeb M.J., Espana F., and Geiger M. Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor 3. J Biol Chem 262 (1987) 15813-15816
45. Baker J.B., Low D.A., and Simmer R.L. Protease nexin: A cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 21 (1980) 37-45
46. Neri Serneri G.G., Gensini G.F., and Poggessi L. Effect of heparin, aspirin or alteplase in reduction of myocardial ischaemia in refractory unstable angina. Lancet 335 (1990) 615-618
47. Collins R., Scrimgeour A., Yusuf S., and Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin: Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 318 (1988) 1162-1173
48. Hyers T.M. Heparin therapy: Regimens and treatment considerations. Drugs 44 (1992) 738-749
49. Hirsh J., and Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. Circulation 89 (1994) 1449-1468
50. Witt D.P., and Lanender A.D. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 4 (1994) 394-400
51. Leung L., Saigo K., and Grant D. Heparin binds to human monocytes and modulates their procoagulant activities and secretory phenotypes. Effect of histidine-rich glycoprotein. Blood 73 (1989) 177-184
52. Handeland G.F., Abildgaard U., Holm H.A., and Arresen E. Dose adjusted heparin treatment of deep venous thrombosis: a comparison to unfractionated and low molecular weight heparin. Eur J Clin Pharmacol 39 (1990) 107-112
53. Eriksson B.I., Kalebo P., Anthmyr B.A., et al. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low molecular weight heparin and unfractionated heparin. J Bone Joint Surg [Am] 73A (1991) 484-493
54. Nelsestuen G.L. Role of gamma carboxy glutamic acid. An unusual transition required for calcium-dependent binding of prothrombin to phospholipid. J Biol Chem 251 (1976) 5648
55. Fasco M.J., Hildebrandt E.F., and Suttie J.W. Evidence that warfarin anticoagulant action involves two distinct reductase activities. J Biol Chem 257 (1982) 11210-11212
56. Hirsch J., and Fuster V. Guide to anticoagulant therapy. Part 2: Oral anticoagulants. Circulation 89 (1994) 1469-1480
57. Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost 66 (1991) 141-152
58. Lefkovits J., and Topol E.J. Direct thrombin inhibitors in cardiovascular medicine. Circulation 90 (1994) 1522-1536
59. Rydel T.J., Ravichandran K.G., Tulinsky A., et al. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 249 (1990) 277-280
60. Eriksson B.I., Ekmann S.T., Kalebo P., et al. Prevention of deep-vein thrombosis after total hip replacement: Direct thrombin inhibition with recombinant hirudin, CCG 39393. Lancet 347 (1996) 635-639
61. Maraganore J.M., Bourdon P., Jablonski J., and Ramachandran K.L. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 229 (1990) 7095-7101
62. Hijikata-Okunomiya F., and Okamoto S. A strategy for rational approach to designing synthetic selective inhibitors. Semin Thromb Hemost 18 (1992) 135-149
63. 4. Thromb Haemost 67 (1992) 325-330
64. Bock L.C., Griffin L.C., Latham J.A., et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 355 (1992) 564-566
65. Kubik M.F., Stephens A.W., Schneider D., et al. High-affinity RNA ligands to human α thrombin. Nucleic Acids Res 22 (1994) 2619-2626
66. Bracht F., and Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun 200 (1994) 933-937
67. Fareed J., and Callas D.D. Pharmacological aspects of thrombin inhibitors: A developmental perspective. Vessels 1 (1995) 15-24
68. Loll P.J., Picot D., and Garavito M. The structured basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nature Struct Biol 2 (1995) 637-643
69. De Caterina R., Sicari R., Bernini W., et al. Benefit/risk profile of combined antiplatelet therapy with ticopidine and aspirin. Thromb Haemost 65 (1991) 504-510
70. Best L.C., McGuire M.B., Jones P.B.B., et al. Mode of action of dipyridamole on human platelets. Thromb Res 16 (1979) 367-379
71. 1 on human platelet function. J Lab Clin Med 109 (1987) 184-190
72. Coller B.S., Scudder L.E., Beer J., et al. Monoclonal antibodies to platelet GP IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 614 (1991) 193-213
73. Ware J., Russell S.R., Vicente V., et al. Nonsense mutation in the glycoprotein Ibα coding sequence associated with Bernard-Soulier syndrome. Proc Natl Acad Sci USA 87 (1990) 2026-2030
74. Simsek S., Admiraal L.G., Modderman P.W., Van der School C.E., and Von dem Borne A.E.G.K. Identification of a homozygous single base pair deletion in the gene coding for the human platelet glycoprotein Ibα causing Bernard-Soulier syndrome. Thromb Haemost 72 (1994) 444-449
75. Kanaji T., Okamura T., Kuroiwa M., et al. Molecular and gentic analysis of two patients with Bernard-Soulier syndrome-Identification of new mutations in the glycoprotein Ibα gene. Thromb Haemost 78 (1997) 1-7
76. Wright S.D., Michaelides K., Johnson D.J.D., West N.C., and Tuddenham E.G.D. Double heterozygosity for mutations in the platelet glycoprotein IX gene in three siblings with Bernard-Soulier syndrome. Blood 81 (1993) 2339-2347
77. Miller J.L., Lyle V.A., and Cunningham D. Mutation of leucine-57 to phenylalanine in a platelet glycoprotein Ibα leucine tandem repeat occurring in patients with an autosomal dominant variant of Bernard-Soulier disease. Blood 79 (1992) 439-446
78. Budarf M.L., Konkle B.A., Ludlow L.B., et al. Identification of a patient with Bernard-Soulier syndrome and a deletion in the DiGeorge/velo-cardiofacial chromosomal region in 22q 11.2. Hum Mol Genet 4 (1995) 763-766
79. Kamura T., Tsuda H., Yae Y., et al. An abnormal fibrinogen Fukuoka II (Gly-Bβ15→CY5) characterized by defective fibrin lateral association and mixed disulfide formation. J Biol Chem 270 (1995) 29392-29399
80. Liu C.Y., Koehn J.A., and Morgan F.J. Characterization of fibrinogen New York 1. J Biol Chem 260 (1985) 4390-4396
81. Yoshida N., Wada H., Morita K., et al. A new congenital abnormal fibrinogen Ise characterized by the replacement of Bβ glycine-15 by cysteine. Blood 77 (1991) 1958-1963
82. Nakahara Y., Tsuji H., Nakagawa K., et al. Genetic analysis in Japanese kindreds of congenital type I antithrombin deficiency causing thrombosis. Thromb Haemost 77 (1997) 616-619
83. Bayston T.A., and Lane D.A. Antithrombin: Molecular basis of deficiency. Thromb Haemost 78 (1997) 339-343
84. Poort S.R., Landolfi R., and Bertina R.M. Compound heterozygosity for two novel missense mutations on the prothrombin gene in a patient with severe bleeding tendency. Thromb Haemost 77 (1997) 610-615
85. Dahlback B. Resistance to activated protein C, the Arg506 to Gln mutation in the factor V gene and venous thrombosis. Functional tests and DNA based assays, pros and cons. Thromb Haemost 73 (1995) 739-742
86. Rees D.C., Cox M., and Clegg J.B. World distribution of factor V Leiden. Lancet 346 (1995) 1133-1134
87. Emmerich J., Alhence-Gelas M., Aillaud M.F., et al. Clinical features in 36 patients homozygous for the Arg506→Gln factor V mutation. Thromb Haemost 77 (1997) 620-623
88. Poot S.R., Rosendaal F.R., Reitsma P.H., and Bertina R.M. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88 (1996) 3698-3703
89. Reitsma P.H. Protein C deficiency: From gene defects to disease. Thromb Haemost 78 (1997) 344-350
90. Aiach M., Gandrille S., and Emmerich J. A review of mutations causing deficiencies of antithrombin, protein C and protein S. Thromb Haemost 74 (1995) 81-89
91. Borgel D., Gandrille S., and Aich M. Protein S deficiency. Thromb Haemost 78 (1997) 351-356
92. Merlini P.A., and Ardissino D. Current status of activation markers in ischemic heart disease: Markers of coagulation activation. Thromb Haemost 78 (1997) 276-279
93. Fareed J., Bick R.L., Hoppensteadt D.A., and Bermes E.W. Molecular markers of hemostatic activation: Applications in the diagnosis of thrombosis and vascular and thrombotic disorders. Clin Appl Thromb Haemost 1 (1995) 87-102
94. Kudryk B., Robinson D., Netre C., et al. Measurement in human blood of fibrinogen/fibrin fragments containing the B beta 15-42 sequence. Thromb Res 25 (1982) 277-291
95. Elms M.J., Bunce I.H., Bundesen P.G., et al. Measurement of crosslinked fibrin degradation products. An immunoassay using monoclonal antibodies. Thromb Haemost 50 (1983) 591-594
96. Galli M., Finazzi G., and Barbui T. Antiphospholipid antibodies: Predictive value of laboratory tests. Thromb Haemost 78 (1997) 75-78
97. Esmon N.L., Smirnov M.D., and Esmon C.T. Thrombogenic mechanisms of antiphospholipid antibodies. Thromb Haemost 78 (1997) 79-82
98. Bizzaro N., and Brandalise M. EDTA-dependent pseudothrombocytopenia. Association with antiplatelet and antiphospholipid antibodies. Am J Clin Pathol 103 (1995) 103-107
99. Michellson A.D. Flow cytometry: A clinical test of platelet function. Blood 87 (1996) 4925-4936
100. Narayanan S. Preanalytical aspects of coagulation testing. Haematologica 80 Suppl to No. 2 (1995) 1-5
101. Adcock D.M., Kressin D.C., and Marlar R.A. Effect of 3.2% vs 3.8% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol 107 (1997) 105-110
102. Koepke J.A., Rogers J., and Allwier M. Pre-instrumental variables in coagulation testing. Am J Clin Pathol 64 (1975) 591-596
103. Ho C., and Wu S. The influence of time, temperature, and packed cell volume on activated partial thromboplastin time and prothrombin time. Thromb Res 62 (1991) 625-633
104. Plumhoff E.A., Thrompson C.K., Fisher P.K., Bowie E.J.W., and Nichols W.L. Effects of specimen storage and handling on coagulation testing. Thromb Haemost 69 (1993) 866 (Abstract)
105. Nelson S., Pritt A., and Marlar R.A. Rapid preparation of plasma for "stat" coagulation testing. Arch Pathol Lab Med 118 (1994) 175-176
106. Files J.C., Malpass T.W., Yee E.K., Richie J.L., and Harker L.A. Studies of human platelet α-granule release in vivo. Blood 58 (1981) 607-618
107. Contant G., Gouault-Heilmann M., and Martinoli J.L. Heparin inactivation during blood storage: Its prevention by blood collection in citric acid, theophylline, adenosine, dipyridamole-CTAD mixture. Thromb Res 31 (1983) 365-374
108. van Den Besselaar A.M.H., Meeuwisse-Braun J., Jansen-Gruter R., and Betina R.M. Monitoring heparin therapy by the activated partial thromboplastin time. The effect of preanalytical conditions. Thromb Haemost 58 (1987) 223-226
109. Kuhne T., Hornstein A., Semple J., et al. Flow cytometric evaluation of platelet activation in blood collected into EDTA vs. Diatube-H, a sodium citrate solution supplemented with theophylline, adenosine and dipyridamole. Am J Hematol 50 (1995) 40-45
110. Engstad C.S., Guteberg T.J., and Osterud B. Modulation of blood cell activation by four commonly used anticoagulants. Thromb Haemost 77 (1997) 690-696
111. Connaghan D.G., Francis C.E., Ryan D.H., and Marder V.J. Prevalence and clinical implications of heparin-associated false positive tests for serum fibrin(ogen) degradation products. Am J Clin Pathol 86 (1986) 304-310
112. Lottenberg R., Sjak-Shie N., Fazleabas A.T., and Roberts R.M. Aprotinin inhibits urokinase but not tissue-type plasminogen activator. Thromb Res 49 (1988) 549-556
113. Mohler M.A., Refino C.J., Chen S.A., Chen A.B., and Hotchkiss A.J. D-Phe-Pro-Arg-chloromethylketone: Its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue type plasminogen activator thrombolytic therapy. Thromb Haemost 56 (1986) 160-164
114. Kluft C., and Verheijen J.H. Leiden Fibrinolysis Working Party. Blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1). Fibrinolysis 4 Suppl 2 (1990) 155-161
115. de Maat M.P.M., Kluft C., de Boer K., Knot E.A.R., and Jie A.F.H. Acid treatment of plasma for the inactivation of plasminogen activator inhibitor-1 (PAI-1). Thromb Res 52 (1988) 425-430
116. Narayanan S. Concepts, principles and applications of selected molecular biology techniques in clinical biochemistry. Adv Clin Chem 32 (1996) 1-38
117. Narayanan S. Preanalytical and analytical pitfalls in molecular biology techniques. J Clin Ligand Assay 20 (1997) 200-205
118. Nowak G., and Bucha E. A new method for the therapeutical monitoring of hirudin. Thromb Haemost 69 (1993) 1306
119. Tsuda H., Iida H., Nakahara M., et al. Etiological analysis of thrombophilia. Jpn J Clin Pathol 45 (1997) 1025-1030 (in Japanese)